NeOnc Technologies Forms Strategic Partnership
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage medical biotechnology firm, has taken a significant step to enhance its clinical trial capabilities by partnering with CBCC Global Research. This collaboration focuses on advancing treatments for brain cancer, allowing for a more robust approach to developing essential therapies.
Expanding Clinical Trial Reach
The partnership aims to conduct clinical trials at 30 FDA-compliant research sites across India. This effort will enable NeOnc to increase patient enrollment and expedite the development of innovative therapies targeting aggressive brain tumors. The initial focus will be on the NEO100-01 Glioblastoma clinical trial, a critical Phase 2a study that assesses the effects of intranasal NEO100, an ultra-purified compound shown to impact advanced brain cancer.
Fostering Advanced Therapies
Amir Heshmatpour, Executive Chairman of NeOnc Technologies, expressed his enthusiasm for the collaboration, noting, "Our partnership with CBCC marks an important milestone in our clinical development strategy. Conducting trials in India allows us to accelerate recruitment while maintaining the highest regulatory standards." He emphasized the goal of completing the Phase 2 enrollment within the year, with results expected shortly thereafter.
Commitment to Quality Standards
The trials will adhere to Good Clinical Practices (GCP) and Good Laboratory Practices (GLP), ensuring the integrity and quality of the data generated. CBCC is set to manage these trials alongside NeOnc’s trusted U.S.-based CRO, Anova Enterprises, promoting a streamlined process that fulfills both regulatory and operational needs.
Impact on Global Patient Access
Dr. Thomas Chen, CEO of NeOnc Technologies, noted, "Advancing therapies for brain cancer is of utmost importance to us. Launching trials in India not only broadens our clinical reach but also facilitates faster access to groundbreaking treatments for a wider range of patients." This initiative underlines NeOnc's dedication to delivering transformative therapies and positively impacting patient outcomes across various demographics.
Profile of NeOnc Technologies Holdings, Inc.
NeOnc Technologies specializes in developing and commercializing treatments for central nervous system (CNS) conditions, specifically focusing on overcoming the blood-brain barrier. Their NEO™ drug development platform has yielded a range of patented drug candidates projected to be effective for many years. The NEO100™-01 and NEO100™-02 therapies are currently advancing through Phase II trials, while both NEO100™-03 and NEO212™ are in the early phases of clinical testing, gaining traction with FDA Fast-Track and Investigational New Drug (IND) designations.
About CBCC Global Research
Based in California, CBCC Global Research is a full-service CRO that provides comprehensive support for clinical trials, including operations, site management, and regulatory compliance. With significant experience in early-stage pharmaceutical and biotechnology development, CBCC has successfully completed over 100 trials across numerous sites, reinforcing its role in facilitating effective clinical trial management.
Frequently Asked Questions
What is the focus of NeOnc Technologies' new partnership?
NeOnc Technologies has partnered with CBCC Global Research to enhance clinical trials for brain cancer treatments, specifically targeting aggressive tumors.
How many clinical trial sites will NeOnc utilize?
NeOnc plans to utilize 30 FDA-compliant clinical research sites across India to facilitate its trials.
What is the NEO100-01 trial about?
The NEO100-01 trial is a Phase 2a study evaluating the survival effects of intranasal NEO100 on glioblastoma patients.
What regulatory standards will the trials adhere to?
The trials will follow Good Clinical Practices (GCP) and Good Laboratory Practices (GLP) to ensure high-quality data and compliance.
What is the future outlook for NeOnc Technologies?
NeOnc Technologies aims to accelerate patient recruitment and improve outcomes with innovative therapies, with results from trials expected within a few months after enrollment completion.
